These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35163285)

  • 21. Retinoprotective effect of agmatine in streptozotocin-induced diabetic rat model: avenues for vascular and neuronal protection : Agmatine in diabetic retinopathy.
    Abo El Gheit RE; Soliman NA; Badawi GA; Madi NM; El-Saka MH; Badr SM; Emam MN
    J Physiol Biochem; 2021 May; 77(2):305-320. PubMed ID: 33635523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
    Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
    PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
    Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG
    Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
    Koike M; Saito H; Kohno G; Takubo M; Watanabe K; Ishihara H
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
    Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
    J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
    Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.
    Obata A; Kubota N; Kubota T; Iwamoto M; Sato H; Sakurai Y; Takamoto I; Katsuyama H; Suzuki Y; Fukazawa M; Ikeda S; Iwayama K; Tokuyama K; Ueki K; Kadowaki T
    Endocrinology; 2016 Mar; 157(3):1029-42. PubMed ID: 26713783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
    Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
    Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
    Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients.
    Otagaki M; Matsumura K; Kin H; Fujii K; Shibutani H; Matsumoto H; Takahashi H; Park H; Yamamoto Y; Sugiura T; Shiojima I
    Cardiovasc Drugs Ther; 2019 Aug; 33(4):435-442. PubMed ID: 31321581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial Effect of Long-Term Administration of Supplement With Trapa Bispinosa Roxb. and Lutein on Retinal Neurovascular Coupling in Type 2 Diabetic Mice.
    Hanaguri J; Yokota H; Kushiyama A; Kushiyama S; Watanabe M; Yamagami S; Nagaoka T
    Front Physiol; 2022; 13():788034. PubMed ID: 35283788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats.
    Takeda K; Ono H; Ishikawa K; Ohno T; Kumagai J; Ochiai H; Matumoto A; Yokoh H; Maezawa Y; Yokote K
    BMJ Open Diabetes Res Care; 2021 Apr; 9(1):. PubMed ID: 33879516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
    Ikeda S; Takano Y; Schwab D; Portron A; Kasahara-Ito N; Saito T; Iida S
    Drug Res (Stuttg); 2019 Jun; 69(6):314-322. PubMed ID: 30103216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
    Rosenwasser RF; Rosenwasser JN; Sutton D; Choksi R; Epstein B
    Drugs Today (Barc); 2014 Nov; 50(11):739-45. PubMed ID: 25525634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.